WallStSmart
CLDI

Calidi Biotherapeutics Inc.

AMEX: CLDI · HEALTHCARE · BIOTECHNOLOGY

$0.19
-2.87% today

Updated 2026-06-05

Market cap
$3.20M
P/E ratio
P/S ratio
50.83x
EPS (TTM)
$-4.17
Dividend yield
52W range
$0 – $13
Volume
5.6M

Calidi Biotherapeutics Inc. (CLDI) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item202020212022202320242025
Operating cash flow$-4.83M$-7.77M$-13.21M$-26.98M$-19.69M$-21.29M
Capital expenditures$351000.00$206000.00$428000.00$585000.00$16000.00$120000.00
Depreciation
Stock-based comp$968000.00$1.33M$6.14M$4.81M$2.96M$2.11M
Free cash flow$-5.18M$-7.98M$-13.64M$-27.57M$-19.71M$-21.41M
Investing cash flow
Financing cash flow
Dividends paid$1.67M$5.67M
Share repurchases
Debt repayment
Net change in cash

Frequently asked questions

How much free cash flow does CLDI generate?

CLDI produced $-21.41M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is CLDI's balance sheet healthy?

CLDI holds $5.60M in cash and equivalents against $600000.00 in long-term debt, on $3.76M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.